Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/phase-1-trial-of-pembrolizumab-administered-concurrently-with-CE5Z2lbDR2
References (25)
-
A. Sharabi, M. Lim, T. DeWeese, C. Drake (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.The Lancet. Oncology, 16 13
-
J. Zeng, A. See, J. Phallen, Christopher Jackson, Z. Belcaid, J. Ruzevick, N. Durham, C. Meyer, T. Harris, E. Albesiano, G. Pradilla, E. Ford, J. Wong, H. Hammers, Dimitris Mathios, B. Tyler, H. Brem, P. Tran, D. Pardoll, C. Drake, M. Lim (2013)
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.International journal of radiation oncology, biology, physics, 86 2
-
T. Mok, Yi‐Long Wu, I. Kudaba, D. Kowalski, B. Cho, H. Turna, G. Castro, V. Srimuninnimit, K. Laktionov, I. Bondarenko, K. Kubota, G. Lubiniecki, Jin Zhang, D. Kush, G. Lopes, G. Adamchuk, M. Ahn, A. Alexandru, O. Altundag, A. Alyasova, O. Andrusenko, K. Aoe, A. Araújo, O. Aren, O. Rodriguez, T. Ativitavas, Oscar Avendano, F. Barata, C. Barrios, C. Beato, Per Bergstrom, D. Betticher, L. Bolotina, Michiel Botha, Sayeuri Buddu, C. Caglevic, A. Cardona, H. Castro, F. Senler, Carlos Cerny, A. Česas, G. Chan, Jian-hua Chang, Gongyan Chen, Xi Chen, S. Cheng, Ying Cheng, N. Cherciu, C. Chiu, S. Cicėnas, D. Ciurescu, G. Cohen, Marcos Costa, P. Danchaivijitr, F. Angelis, S. Azevedo, M. Dediu, Ts Deliverski, P. Marchi, Flor Valles, Z. Ding, Boyan Doganov, L. Dreosti, R. Duarte, Regina Edusma-Dy, S. Emelyanov, M. Erman, Yun Fan, L. Fein, Jifeng Feng, D. Fenton, G. Fernandes, C. Ferreira, F. Franke, H. Freitas, Y. Fujisaka, H. Galindo, Christina Galvez, D. Ganea, N. Gil, G. Girotto, E. Goker, T. Goksel, Gonzalo Aubin, Luis Wolff, H. Griph, M. Gumus, Jacqueline Hall, Greg Hart, L. Havel, Jianxing He, Yong He, C. Hernández, V. Hespanhol, T. Hirashima, Chung-man. Ho, A. Horiike, Y. Hosomi, K. Hotta, M. Hou, S. How, T. Hsia, Yi Hu, M. Ichiki, F. Imamura, O. Ivashchuk, Y. Iwamoto, J. Jaal, J. Jassem, Christa Jordaan, R. Juergens, D. Kaen, E. Kalinka‐Warzocha, N. Karaseva, B. Karaszewska, A. Każarnowicz, K. Kasahara, N. Katakami, T. Kato, T. Kawaguchi, J. Kim, K. Kishi, V. Kolek, Marchela Koleva, P. Kolman, L. Koubková, R. Kowalyszyn, D. Kowalski, K. Koynov, D. Ksienski, T. Kurata, G. Kuusk, L. Kuzina, I. Laczó, G. Ladrera, K. Laktionov, G. Landers, S. Lazarev, G. Lerzo, Krzysztof Kmak, Wei Li, C. Liam, Igor Lifirenko, O. Lipatov, Xiaoqing Liu, Zhe Liu, S. Lo, Valeria Lopes, Karla Lopez, Shun Lu, G. Martinengo, L. Mas, M. Matrosova, Rumyana Micheva, Z. Milanova, L. Miron, Tony Mok, M. Molina, S. Murakami, Y. Nakahara, Tien Nguyen, T. Nishimura, A. Ochsenbein, T. Ohira, Ronny Ohman, C. Ong, G. Ostoros, X. Ouyang, E. Ovchinnikova, O. Ozyılkan, L. Petruželka, Xuan Pham, P. Picon, B. Pikó, A. Poltoratsky, Olga Ponomarova, Patrice Popelkova, G. Purkalne, S. Qin, R. Ramlau, Bernardo Rappaport, Felipe Rey, E. Richardet, J. Roubec, P. Ruff, A. Rusyn, H. Saka, J. Salas, Mario Sandoval, L. Santos, T. Sawa, K. Seetalarom, M. Seker, N. Seki, Freddy Seolwane, L. Shepherd, Sergii Shevnya, A. Shimada, Y. Shparyk, I. Sinielnikov, D. Sirbu, O. Smaletz, João Soares, A. Sookprasert, G. Speranza, V. Sriuranpong, Zinaida Stara, W. Su, S. Sugawara, W. Szpak, Kazuhisa Takahashi, N. Takigawa, Hiroshi Tanaka, Jerry Bing, Q. Tang, P. Taranov, H. Tejada, L. Tho, Yoshitaro Torii, Dmytro Trukhyn, M. Turdean, H. Turna, G. Ursol, J. Vaňásek, M. Varela, M. Vallejo, Luis Vera, A. Victorino, T. Vlásek, I. Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih‐Hsin Yang, T. Yokoyama, T. Yokoyama, H. Yoshioka, F. Yumuk, A. Zambrano, J. Zarbá, O. Zarubenkov, Marius Žemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, A. Zippelius (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 393
-
Translational Lung Cancer Research -
L. Bracci, G. Schiavoni, A. Sistigu, F. Belardelli (2013)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancerCell Death and Differentiation, 21
-
M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, K. Vandormael, A. Riccio, Jing Yang, M. Pietanza, J. Brahmer (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 7
-
J. Bradley, R. Paulus, R. Komaki, G. Masters, G. Blumenschein, S. Schild, J. Bogart, Chen Hu, K. Forster, A. Magliocco, V. Kavadi, Y. Garces, S. Narayan, P. Iyengar, C. Robinson, R. Wynn, C. Koprowski, J. Meng, J. Beitler, R. Gaur, W. Curran, H. Choy (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.The Lancet. Oncology, 16 2
-
G. Durm, S. Althouse, A. Sadiq, S. Jalal, S. Jabbour, R. Zon, G. Kloecker, W. Fisher, K. Reckamp, E. Kio, R. Langdon, B. Adesunloye, R. Gentzler, N. Hanna (2018)
Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.Journal of Clinical Oncology, 36
-
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
-
Xiaomei Gong, Xue-Fei Li, T. Jiang, Huikang Xie, Zhengfei Zhu, F. Zhou, Caicun Zhou (2017)
Combined Radiotherapy and Anti–PD‐L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 12
-
S. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K. Lee, M. Wit, B. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Young‐Chul Kim, C. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J. Gray, L. Paz-Ares, J. Carpeño, C. Faivre-Finn, M. Reck, J. Vansteenkiste, D. Spigel, C. Wadsworth, G. Melillo, Maria Taboada, P. Dennis, M. Özgüroğlu (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCThe New England Journal of Medicine, 379
-
Sanne Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martínez-Martí, A. Tufman, Maarten Lambrecht, N. Andratschke, A. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R. Stahel, J. Vansteenkiste, D. Ruysscher (2019)
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.Lung cancer, 133
-
R. Vatner, B. Cooper, C. Vanpouille-Box, S. Demaria, S. Formenti (2014)
Combinations of Immunotherapy and Radiation in Cancer TherapyFrontiers in Oncology, 4
-
M. Roselli, V. Cereda, M. Bari, V. Formica, A. Spila, C. Jochems, B. Farsaci, R. Donahue, J. Gulley, J. Schlom, F. Guadagni (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cellsOncoimmunology, 2
-
J. Gray, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Kurata, A. Chiappori, K. Lee, B. Cho, D. Planchard, L. Paz-Ares, C. Faivre-Finn, J. Vansteenkiste, D. Spigel, C. Wadsworth, Maria Taboada, P. Dennis, M. Ozguroglu, S. Antonia (2019)
Three-year overall survival update from the PACIFIC trial.Journal of Clinical Oncology
-
R. Santana-Davila, K. Devisetty, A. Szabo, R. Sparapani, C. Arce-Lara, E. Gore, A. Moran, C. Williams, M. Kelley, J. Whittle (2015)
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 6
-
N. Shaverdian, A. Lisberg, K. Bornazyan, D. Veruttipong, J. Goldman, S. Formenti, E. Garon, Percy Lee (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.The Lancet. Oncology, 18 7
-
W. Curran, R. Paulus, C. Langer, R. Komaki, Jin Lee, S. Hauser, B. Movsas, T. Wasserman, S. Rosenthal, E. Gore, M. Machtay, W. Sause, J. Cox (2011)
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.Journal of the National Cancer Institute, 103 19
-
A. Aupérin, C. Péchoux, E. Rolland, W. Curran, K. Furuse, P. Fournel, J. Belderbos, G. Clamon, H. Ulutin, R. Paulus, T. Yamanaka, M. Bozonnat, A. Uitterhoeve, Xiaofei Wang, L. Stewart, R. Arriagada, S. Burdett, J. Pignon (2010)
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 13
-
L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, J. Mazières, B. Hermes, F. Senler, T. Csőszi, A. Fülöp, J. Rodríguez-Cid, Jonathan Wilson, S. Sugawara, T. Kato, K. Lee, Ying Cheng, S. Novello, B. Halmos, Xiaodong Li, G. Lubiniecki, B. Piperdi, D. Kowalski (2018)
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 379
-
Liufu Deng, H. Liang, Byron Burnette, M. Beckett, T. Darga, R. Weichselbaum, yang-xin fu (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.The Journal of clinical investigation, 124 2
-
W. Theelen, H. Peulen, F. Lalezari, V. Noort, J. Vries, J. Aerts, D. Dumoulin, I. Bahce, A. Niemeijer, A. Langen, K. Monkhorst, P. Baas (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.JAMA oncology
-
Zibing Wang, B. Till, Q. Gao (2017)
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cellsOncoImmunology, 6
-
M. Dolled-Filhart, Darren Locke, Tiffany Murphy, F. Lynch, J. Yearley, D. Frisman, R. Pierce, R. Weiner, Dianna Wu, K. Emancipator (2016)
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.Archives of pathology & laboratory medicine, 140 11
-
L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. Angelis, M. Dómine, P. Clingan, M. Hochmair, S. Powell, S. Cheng, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. Gray, J. Vida, Ziwen Wei, Jing Yang, H. Raftopoulos, C. Pietanza, M. Garassino (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 378
- Publisher
- American Medical Association
- Copyright
- Copyright 2020 American Medical Association. All Rights Reserved.
- ISSN
- 2374-2437
- eISSN
- 2374-2445
- DOI
- 10.1001/jamaoncol.2019.6731
- Publisher site
- See Article on Publisher Site
Abstract
This phase 1 nonrandomized controlled trial assesses the safety and tolerability of programmed cell death 1 inhibition concurrently with definitive chemoradiotherapy compared with programmed cell death 1 inhibition and radiotherapy in patients with non–small cell lung cancer.
Journal
JAMA Oncology – American Medical Association
Published: Jun 20, 2020